fechnology Centar 2100



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Tolle et al.

Serial No.

09/941,496

Filed

August 29, 2001

For

SYSTEM AND METHODS FOR GENERATING PHYSICIANS

PROFILES CONCERNING PRESCRIPTION THERAPY

PRACTICES

Examiner

To Be Assigned

Group Art Unit

2166

New York, New York 10112 Date: January 7, 2002

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on:

January 7, 2002 Date of Deposit

Walter M. Egbert III

Attorney Name

37,317

Registration No.

Signature

January 7, 2002

Date of Signature

Commissioner of Patents Washington, DC 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97 (b), applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449.

3944 – (065855.0127) PATENT

This statement is submitted more than three months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Information Disclosure Statement requires no fee. However, if for any reason a fee is due, the Commissioner is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 02-4377. A duplicate copy of this letter is transmitted herewith.

It is respectfully requested that these references be (1) fully considered by the Patent and Trademark Office during examination of this application; and (2) printed on any patent which may issue on this application. Applicants request that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.

Early and favorable action is respectfully requested.

Respectfully submitted,

Walter M. Egbert, III

Patent Office Reg. No. 37,317

Attorney for Applicant(s)

(212) 408-2561

Attorneys for Applicants

BAKER BOTTS L.L.P. 30 Rockefeller Plaza New York, NY 10112 (212) 408-2561

Enclosures

	 						-						
Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office						Atty. Docket No. Serial No. A33944 (065855.0127) 09/941,496							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						Applicant Tolle et al.							
						Filing Date Group August 29, 2001 2166							
JAN 1	5 2002	ر م ارد ارد											
*Exam. Filing Date													
	ATIFAR	· · · ·				_				Filing Date			
Init.	Document No.				Date	Name		Class	s Subclass ifAppro				
			+ +										
										رت ک			
									lolog	2 0			
									y Cer				
									<u></u>				
									100	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			
				FOI	DEICN DAT	ENT DOCUMENTS	_						
	Document No. Date				Country Class Subclass <u>Translation</u>								
									IN IN	<u> </u>			
		· <u>·</u> · · · · · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·								
	OT Dend	THER I	OCU.	MENTS Press Re	(including)	Author, Title Date, Pe	rtinent	Pages,	Etc.)	ormation to			
	Bette	er Direct	Pharmac	ceutical In	dustry's Sales F	Forces", September 14, 2000		to Don't	of New III	ornation to			
	Deno Phar	drite Corp maceutic	oration, al Indus	Press Retry", Septe	lease, "Dendrite ember 29, 2000	Demonstrates How to Acco	ess To Its	Group 2166 Class Subclass Filing Date if Appropriate Change Cha					
	Quin	Quintiles Transnational, Web pages "The Quinternet Services, Rx Market Monitor Selection", June 20, 1999.											
	_												
NY02:359903.1													
Examiner Date Considered													

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.